Kezar Life Sciences is scheduled to resume trading at 4:40 pm ET, with quotation set to resume at 4:35 pm ET, according to Nasdaq. Shares were halted, pending news, ahead of the company announcing a strategic restructuring, 41% workforce reduction, and CEO change.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KZR:
- Kezar Life Sciences price target raised to $20 from $18 at H.C. Wainwright
- Kezar Life Sciences enters into collaboration pact with Everest Medicines
- Kezar Life Sciences downgraded to Equal Weight from Overweight at Wells Fargo
- Kezar Life Sciences price target lowered to $18 from $19 at H.C. Wainwright
- Kezar Life Sciences reports Q2 EPS (34c), consensus (32c)
